Literature DB >> 23315611

Amlodipine--not a significant contributor to clopidogrel non-response?

Rolf P Kreutz, David A Flockhart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23315611      PMCID： PMC4064296          DOI： 10.1136/heartjnl-2012-303214

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  17 in total

1.  Clopidogrel with or without omeprazole in coronary artery disease.

Authors:  Deepak L Bhatt; Byron L Cryer; Charles F Contant; Marc Cohen; Angel Lanas; Thomas J Schnitzer; Thomas L Shook; Pablo Lapuerta; Mark A Goldsmith; Loren Laine; Benjamin M Scirica; Sabina A Murphy; Christopher P Cannon
Journal:  N Engl J Med       Date:  2010-10-06       Impact factor: 91.245

2.  Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.

Authors:  D J Angiolillo; C M Gibson; S Cheng; C Ollier; O Nicolas; L Bergougnan; L Perrin; F P LaCreta; F Hurbin; M Dubar
Journal:  Clin Pharmacol Ther       Date:  2010-09-15       Impact factor: 6.875

3.  Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events.

Authors:  Morten Schmidt; Martin B Johansen; Douglas J Robertson; Michael Maeng; Anne Kaltoft; Lisette O Jensen; Hans-Henrik Tilsted; Hans E Bøtker; Henrik Toft Sørensen; John A Baron
Journal:  Eur J Clin Invest       Date:  2011-08-11       Impact factor: 4.686

4.  Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.

Authors:  Jae-Sik Jang; Kyoung-Im Cho; Han-Young Jin; Jeong-Sook Seo; Tae-Hyun Yang; Dae-Kyeong Kim; Dong-Soo Kim; Sang-Hoon Seol; Doo-Il Kim; Bo-Hyun Kim; Yong Hyun Park; Hyung-Gon Je; Young-Hoon Jeong; Seung-Whan Lee
Journal:  Am J Cardiol       Date:  2012-05-15       Impact factor: 2.778

5.  Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.

Authors:  Christopher W Good; Steven R Steinhubl; Danielle M Brennan; A Michael Lincoff; Eric J Topol; Peter B Berger
Journal:  Circ Cardiovasc Interv       Date:  2012-02-07       Impact factor: 6.546

6.  Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.

Authors:  Heleen J Bouman; Ankie M Harmsze; Jochem W van Werkum; Nicoline J Breet; Th O Bergmeijer; Hugo Ten Cate; Christian M Hackeng; Vera H M Deneer; Jurriën M Ten Berg
Journal:  Heart       Date:  2011-05-31       Impact factor: 5.994

7.  The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.

Authors:  Ankie M Harmsze; Karen Robijns; Jochem W van Werkum; Nicoline J Breet; Christian M Hackeng; Jurrien M Ten Berg; Hendrik J T Ruven; Olaf H Klungel; Anthonius de Boer; Vera H M Deneer
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

8.  Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.

Authors:  A M Harmsze; J W van Werkum; P C Souverein; N J Breet; H J Bouman; C M Hackeng; H J T Ruven; J M ten Berg; O H Klungel; A de Boer; V H M Deneer
Journal:  J Thromb Haemost       Date:  2011-10       Impact factor: 5.824

Review 9.  Clopidogrel-drug interactions.

Authors:  Eric R Bates; Wei C Lau; Dominick J Angiolillo
Journal:  J Am Coll Cardiol       Date:  2011-03-15       Impact factor: 24.094

10.  Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.

Authors:  Nagy A Farid; David S Small; Christopher D Payne; Joseph A Jakubowski; John T Brandt; Ying G Li; C Steven Ernest; Daniel E Salazar; Christopher S Konkoy; Kenneth J Winters
Journal:  Pharmacotherapy       Date:  2008-12       Impact factor: 4.705
View more
  2 in total

1.  Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention.

Authors:  Rolf P Kreutz; Jeffrey A Breall; Anjan Sinha; Elisabeth von der Lohe; Richard J Kovacs; David A Flockhart
Journal:  Clin Pharmacol       Date:  2016-06-03

2.  Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention.

Authors:  Fakilahyel S Mshelbwala; Daniel W Hugenberg; Rolf P Kreutz
Journal:  Clin Pharmacol       Date:  2020-04-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.